- SkyePharma PLC
- GlaxoSmithKline PLC
- Endo Pharmaceuticals Inc.
- Acambis PLC
- UCB Celltech
- Alkermes PLC
- Johnson & Johnson
- Enzon Pharmaceuticals Inc.
- Paladin Labs Inc.
- Mundipharma Laboratories GmbH
- Elan Corp. PLC
- Reliant Pharmaceuticals Inc.
- King Pharmaceuticals Inc.
- Schering-Plough Corp.
- Quintiles Transnational Holdings Inc.
- Shire PLC
- Reliance GeneMedix PLC
- CTI BioPharma Corp.
- Cell Therapeutics Europe SRL
- Barr Laboratories Inc.
- Warner Chilcott PLC
- Acambis PLC
- Baxter International Inc.
- CIMA Labs Inc.
- Cephalon Inc.
- SkyePharma raises $30mm for pain drug
- SkyePharma gets $30mm over two years from royalty fund
- SkyePharma buys 40% of RTP Pharma
- SkyePharma buys the rest of RTP for $20.6mm
- Endo licenses pain drugs from SkyePharma; terminated
- Enzon, SkyePharma sign two drug delivery deals
- Mundipharma gets European rights to SkyePharma's DepoCyte
- Skyepharma buys Jago in earn-out, initial payment is $195mm
- SkyePharma to develop Geomatrix version of SB's Requip
- Elan acquires Athena Neurosciences
- SkyePharma applies Geomatrix to King's Altace
- SkyePharma applies DepoFoam to GeneMedix's interferon a-2b
- Chiron buys PowderJect for £542mm
- Cell Therapeutics acquires Novuspharma
- J&J agrees to acquire Alza for stock
- aaiPharma, CIMA enter merger agreement; terminated
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.